These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28845406)

  • 21. Response to hydroxyurea therapy in beta-thalassemia.
    Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
    Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
    el-Hazmi MA; al-Momen A; Warsy AS; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F
    Acta Haematol; 1995; 93(2-4):57-61. PubMed ID: 7543719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxyurea in thalassemia intermedia--a promising therapy.
    Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients.
    Bordbar MR; Silavizadeh S; Haghpanah S; Kamfiroozi R; Bardestani M; Karimi M
    Iran Red Crescent Med J; 2014 Jun; 16(6):e18028. PubMed ID: 25068055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
    Mtvarelidze Z; Kvezereli-Kopadze A; Kvezereli-Kopadze M; Mestiashvili I
    Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
    El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
    Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic Modifiers of Sickle Cell Disease: A Genotype-Phenotype Relationship Study in a Cohort of 82 Children on Mayotte Island.
    Muszlak M; Pissard S; Badens C; Chamouine A; Maillard O; Thuret I
    Hemoglobin; 2015; 39(3):156-61. PubMed ID: 25806420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do alpha deletions influence hydroxyurea response in thalassemia intermedia?
    Panigrahi I; Dixit A; Arora S; Kabra M; Mahapatra M; Choudhry VP; Saxena R
    Hematology; 2005 Feb; 10(1):61-3. PubMed ID: 16019448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.
    Tafrali C; Paizi A; Borg J; Radmilovic M; Bartsakoulia M; Giannopoulou E; Giannakopoulou O; Stojiljkovic-Petrovic M; Zukic B; Poulas K; Stavrou EF; Lambropoulou P; Kourakli A; Felice AE; Papachatzopoulou A; Philipsen S; Pavlovic S; Georgitsi M; Patrinos GP
    Pharmacogenomics; 2013 Apr; 14(5):469-83. PubMed ID: 23556445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Featured Article: Modulation of fetal hemoglobin in hereditary persistence of fetal hemoglobin deletion type-2, compared to Sicilian δβ-thalassemia, by BCL11A and SOX6-targeting microRNAs.
    Fornari TA; Lanaro C; Albuquerque DM; Ferreira R; Costa FF
    Exp Biol Med (Maywood); 2017 Feb; 242(3):267-274. PubMed ID: 27591578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
    Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
    Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy in β-Thalassemia Patients.
    Zohaib M; Ansari SH; Hashim Z; Shamsi TS; Zarina S
    J Clin Pharmacol; 2016 Jul; 56(7):869-74. PubMed ID: 26608512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.
    Dehury S; Purohit P; Patel S; Meher S; Kullu BK; Sahoo LK; Patel NK; Mohapatra AK; Das K; Patel DK
    Pediatr Blood Cancer; 2015 Jun; 62(6):1017-23. PubMed ID: 25546091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Aγ-globin G->A gene polymorphism associated with β
    Breveglieri G; Bianchi N; Cosenza LC; Gamberini MR; Chiavilli F; Zuccato C; Montagner G; Borgatti M; Lampronti I; Finotti A; Gambari R
    BMC Med Genet; 2017 Aug; 18(1):93. PubMed ID: 28851297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single nucleotide polymorphism in the HBBP1 gene in the human β-globin locus is associated with a mild β-thalassemia disease phenotype.
    Giannopoulou E; Bartsakoulia M; Tafrali C; Kourakli A; Poulas K; Stavrou EF; Papachatzopoulou A; Georgitsi M; Patrinos GP
    Hemoglobin; 2012; 36(5):433-45. PubMed ID: 22943111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the Relationship Between Hb F Levels and Nucleated Red Blood Cells with Morbidity in Non Transfusion-Dependent Thalassemia Patients.
    Karimi M; Jooya P; Haghpanah S; Mokhtari M; Rezaei N; Fath M; Parand S
    Hemoglobin; 2016 Aug; 40(4):250-6. PubMed ID: 27211282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study.
    Tavakkoli F; Nahavandi M; Wyche MQ; Castro O
    Clin Ther; 2005 Jul; 27(7):1083-8. PubMed ID: 16154487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
    Karimi M; Mohammadi F; Behmanesh F; Samani SM; Borzouee M; Amoozgar H; Haghpanah S
    Eur J Haematol; 2010 Jan; 84(1):52-8. PubMed ID: 19799627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
    Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of cholelithiasis in patients with Beta-thalassemia intermedia with and without hydroxyurea.
    Khavari M; Hamidi A; Haghpanah S; Bagheri MH; Bardestani M; Hantooshzadeh R; Karimi M
    Iran Red Crescent Med J; 2014 Jul; 16(7):e18712. PubMed ID: 25237586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.